Navigation Links
SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System
Date:5/19/2009

VANCOUVER, May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has reported positive outcomes from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express(2)(R) Paclitaxel-Eluting Coronary Stent System. SYNTAX-LE MANS is a substudy of the landmark SYNTAX trial, the first randomized, controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS Stent to coronary artery bypass graft (CABG) surgery in patients with left main disease and/or significant narrowing of all three coronary arteries (three-vessel disease). The substudy data were presented by A. Pieter Kappetein, M.D., Ph.D., at the annual EuroPCR Scientific Program in Barcelona.

SYNTAX-LE MANS compares late angiographic and clinical outcomes in 263 patients with left main disease (149 treated with the TAXUS Stent and 114 treated with CABG). It is designed to assess 15-month patency (vessel openness) and the safety of stents and grafts in this high-risk population; it includes separate primary endpoints for each treatment arm. For PCI patients, the primary endpoint is the rate of long-term patency (defined here as (less than)50% stenosis) of the treated lesion sites. For CABG patients, the primary endpoint is the ratio of obstructed/occluded grafts (defined here as (greater than or equal to)50% stenosis) to total placed grafts. Results were presented separately for each group, and no formal statistical inferences between the two groups were made due to the different primary endpoints. Results were also broken out by left main lesion location, including distal and non-distal.

For those patients receiving a TA
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery
2. Boston Scientific Welcomes Launch of Syntax Score Website
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
8. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
9. Video shows buckyballs form by shrink wrapping
10. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Md. , Aug. 19, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today that its novel ... at the 54 th Interscience Conference on ... Washington D.C. ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... and data storage may someday run on ... to read and write digital information, outperforming ... But ferroelectrics must first overcome a few ... of "forgetting" stored data. , Now, ... Brookhaven National Laboratory have discovered nanoscale asymmetries ...
(Date:8/18/2014)... 18, 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ... manufacturing and marketing of innovative therapies for autoimmune diseases ... providing a second notice of TNI BioTech,s annual meeting ... announcement, Noreen Griffin , founder and CEO of ... your participation in the Annual Meeting. On behalf of ...
Breaking Biology Technology:Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4
... (Nasdaq:,AWRE), a leading supplier of broadband technology and biometrics ... an extension to,the program originally authorized on August 28, ... up to $5 million worth of shares of,the Company,s ... until December,31, 2009 at prevailing market prices. The Board ...
... Net Revenues, $0.10 Net Income Per Share, SAN ... VNUS ), a leading provider of medical devices,for ... its,financial results for the third quarter ended September 30, ... 2008 increased 32% to $23.1,million compared with $17.5 million ...
... Transgenomic, Inc. (OTC,Bulletin Board: TBIO) today announced financial results ... results are presented in,the tables that follow., Third ... $5.4 million during the third,quarter of 2008, compared to ... from continuing operations was $2.9 million or 54,percent during ...
Cached Biology Technology:Aware, Inc. Announces Extension of Stock Repurchase Plan 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 2VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 3VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 4VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 5VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 6VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 7VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 8VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 9VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007 10Transgenomic, Inc. Reports Third Quarter 2008 Results 2Transgenomic, Inc. Reports Third Quarter 2008 Results 3Transgenomic, Inc. Reports Third Quarter 2008 Results 4Transgenomic, Inc. Reports Third Quarter 2008 Results 5Transgenomic, Inc. Reports Third Quarter 2008 Results 6Transgenomic, Inc. Reports Third Quarter 2008 Results 7
(Date:8/19/2014)... Daylight was breaking over the central Pacific and ... about a dozen scientists strategized for the day ahead. ... to collect water samples around the southern Line Islands, ... gizmos and delicate machinery strewn throughout the 158-foot research ... research group to bring a DNA sequencer out into ...
(Date:8/18/2014)... , August 19, 2014 ... biometric authentication in smart devices  Trustonic, ... for smart devices, and Fingerprint Cards AB (FPC) ... of FIDO Ready™ secure biometric authentication on connected ... touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) and ...
(Date:8/18/2014)... species native to a major Arizona watershed may lose ... as surface water flow is reduced by the effects ... these fish species, found in the Verde River Basin, ... easy access to various resources throughout the river and ... (Rhinichthys osculus), roundtail chub (Gila robusta) and Sonora sucker ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... , RIDGE, N.Y., Oct. 21 What,s the cost ... preventing accidental death resulting from prescription medication abuse, there,s ... be unaware that the lock-boxes they,ve installed are not ... drugs. That,s why MEDNET(TM), a national leader in premium-quality ...
... CHAPEL HILL Scientists at the University of ... the University of California, San Francisco have developed and ... for existing drugs. The researchers developed a computational ... known drugs are to the naturally occurring binding partners ...
... 4, 2009) For more than 25 years, all ... Strombus gigas ) have been unsuccessfuluntil now. For the ... beaded (nucleated) and non-beaded cultured pearls from the queen ... University,s Harbor Branch Oceanographic Institute (HBOI). With less than ...
Cached Biology News:MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3
... Ac-DEVD-CHO is an inhibitor ... The concentration of inhibitor ... activity must be determined ... Ten micromolar inhibitor is ...
Human RELT/TNFRSF19L MAb (Clone 238104)...
homeo box D3, mRNA...
Human TSLP MAb (Clone 258136)...
Biology Products: